This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

The report estimates that out-of-pocket costs for the 10 drugs will fall nearly 50% in 2026 versus 2025 in all 56 stand-alone prescription drug plans in California, Florida, Texas, New York, ‌and ...

After reportedly flirting with going public for years, the artificial intelligence-powered drug developer Insilico Medicine has laid out plans to raise about $292 million through a listin | The IPO ...

Eli Lilly announced this morning that its investigational obesity pill largely helped patients maintain their weight loss ...

In topline results of the ATTAIN-MAINTAIN trial, people who lost weight with an injectable GLP-1 were able to keep weight off when switched to an oral GLP-1, Eli Lilly announced.For ATTAIN-MAINTAIN, ...

Dec 18 () - Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ​drugs, the company said on Thursday, in a boost to ‌deliver a more ...